Prosecution Insights
Prosecution Insights
5 pending office actions • 4 clients • 4 examiners • 2 art units • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting only | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONIGLIO, AUDREA JUNE BUCKLEY | 2 | 52.8% | +21.2% |
| WILKENS, JANET MARIE | 1 | 72.5% | +12.6% |
| MONSHIPOURI, MARYAM | 1 | 79.0% | +37.3% |
| MERTZ, PREMA MARIA | 1 | 71.4% | +35.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18486323 | FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE | CONIGLIO, AUDREA JUNE BUCKLEY | 2d overdue |
| 18486306 | FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE | CONIGLIO, AUDREA JUNE BUCKLEY | 2d overdue |
| 19073510 | COLLAPSIBLE ADJUSTABLE HEIGHT TABLE | WILKENS, JANET MARIE | — |
| 18805099 | MOLECULAR SWITCHES | MONSHIPOURI, MARYAM | — |
| 18315633 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | MERTZ, PREMA MARIA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| GOLO LLC | 2 |
| Evo Inventions LLC | 1 |
| Bioverde Tech LLC | 1 |
| ACTIVE BIOTECH AB | 1 |
| Art Unit | Apps |
|---|---|
| 1617 | 2 |
| 1674 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19073510 | COLLAPSIBLE ADJUSTABLE HEIGHT TABLE | Evo Inventions LLC | WILKENS, JANET MARIE | §103 | Non-Final OA | — | Pending | Mar 07, 2025 | |
| 18805099 | MOLECULAR SWITCHES | Bioverde Tech LLC | MONSHIPOURI, MARYAM | DP | Non-Final OA | — | Pending | Aug 14, 2024 | |
| 18486323 | FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE | Golo LLC | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | DP | Final Rejection | 2d overdue | Pending | Oct 13, 2023 |
| 18486306 | FORMULATIONS FOR WEIGHT LOSS AND METHODS OF USE | Golo LLC | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | DP | Final Rejection | 2d overdue | Pending | Oct 13, 2023 |
| 18315633 | COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT | Active Biotech AB | MERTZ, PREMA MARIA | 1674 | §103 | Non-Final OA | — | Pending | May 11, 2023 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial